Search

Displaying results 2861 - 2870 of 10000 in total
  1. Drug

    Poliovirus type 2 antigen (formaldehyde inactivated)

    go.drugbank.com/drugs/DB10796
    ApprovedInvestigational

    Poliovirus type 2 antigen is a suspension of poliovirus Type 2 (MEF-1) used in the active immunization of infants (as young as 6 weeks of age), children, and adults for the prevention of poliomyelitis

    Mixtures: HEXAXIM 0.5 ML IM ENJEKSİYONLUK SÜSPANSİYON İÇEREN FLAKON, 1 ADET, VeroPol Injektionslösung in einer Fertigspritze
  2. Drug

    Anthralin

    go.drugbank.com/drugs/DB11157
    Approved

    Anthralin (1,8‐dihydroxy‐9anthrone, dithranol) is an older anti-psoriatic agent that was first synthesized as a derivative of chrysarobin, obtained from the araroba tree in Brazil over 100 years ago. … Anthralin has also been studied in the treatment of warts, showing promising results [A32307].

    Mixtures: PSORAKS 30 GR KREM, PSORAKS 30 GR FORT KREM
  3. Drug

    GC012F

    go.drugbank.com/drugs/DB22406
    Investigational

    GC012F is under investigation in clinical trial NCT06419166 (An Exploratory Clinical Study of GC012F Injection for Refractory gMG).

  4. Drug

    KIN-3248

    go.drugbank.com/drugs/DB17587
    Investigational

    It was designed to mainly target FGFR2 and FGFR3 alterations, which act as oncogenic drivers in 10-20% of cholangiocarcinoma and 20-35% of urothelial cancers, respectively. … [A257714] While effective, disease progression may occur 6 to 8 months after treatment with currently approved FGFR inhibitors is started, and this effect is usually associated with on-target resistance

  5. Drug

    Racemethionine

    go.drugbank.com/drugs/DB13972
    Approved

    A preparation of methionine that includes a mixture of D-methionine and L-methionine isomers.

    Mixtures: AMINOPLASMAL® 10% E, AMINOPLASMAL® 10% E
  6. Drug

    Olcegepant

    go.drugbank.com/drugs/DB04869
    Investigational

    Olcegepant is undergoing phase II trials in Europe and the US, with preliminary results suggesting that CGRP antagonists may represent a potential new approach to the treatment of migraine. … Boehringer Ingelheim Pharmaceuticals’ olcegepant (BIBN 4096) is a selective Calcitonin Gene-Related Peptide (CGRP) antagonist, a new class of drugs in development for the treatment of acute migraine attacks

  7. Drug

    Poliovirus type 3 antigen (formaldehyde inactivated)

    go.drugbank.com/drugs/DB10797
    ApprovedInvestigational

    Poliovirus type 3 antigen is a suspension of poliovirus Type 3 (Saukett) used in the active immunization of infants (as young as 6 weeks of age), children, and adults for the prevention of poliomyelitis

    Mixtures: HEXAXIM 0.5 ML IM ENJEKSİYONLUK SÜSPANSİYON İÇEREN FLAKON, 1 ADET, VeroPol Injektionslösung in einer Fertigspritze
  8. Drug

    Influenza B virus B/Washington/02/2019 recombinant hemagglutinin antigen

    go.drugbank.com/drugs/DB15702
    ApprovedWithdrawn

    Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.

    Mixtures: Fluarix Tetra Injektionssuspension in einer Fertigspritze, FluQuadri Quadrivalent Influenza Vaccine, 0.5 ml
  9. Drug

    Elacestrant

    go.drugbank.com/drugs/DB06374
    ApprovedInvestigational

    [L44918,L44948] It received a similar approval in the EU in September 2023. … Elacestrant is a non-steroidal small molecule and an estrogen receptor (ER) antagonist.

  10. Drug

    ME-344

    go.drugbank.com/drugs/DB13062
    Investigational

    ME-344 has been used in trials studying the treatment of Solid Tumors.